Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor alpha joining 14 (TRAJ14) is a gene segment in the human genome that encodes one of the joining (J) segments used during the somatic recombination of T cell receptor (TCR) alpha chains[6]. TRAJ14 is not a full-length receptor or enzyme itself but rather a genetic element contributing to the diversity of the T cell receptor repertoire. During T cell development, TRAJ14 can be joined to various TCR alpha variable (V) segments and paired with a TCR alpha constant (C) region via V-J recombination, thereby enabling the generation of T cell receptors capable of recognizing a vast array of antigens presented by the major histocompatibility complex (MHC)[6][7]. There are no known drugs or therapies that directly target TRAJ14, nor does TRAJ14 itself have a direct, stand-alone role in disease beyond its participation as a component of TCR diversity, which is essential for robust adaptive immunity[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor alpha joining 14 (TRAJ14).